QPCT and Alzheimer disease: Optimized or pharmacological selenium intakes combined with incretin-targeting agents (e.g., GLP-agonists and dipeptidyl-peptidase IV inhibitors) in addition to glutaminyl cyclase inhibitors may be proposed as a possible treatment strategy for AD.